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ABSTRACT
MiR-29 family dysregulation occurs in various cancers including breast cancers. 
We investigated miR-29b-1 functional role in human triple negative breast cancer 
(TNBC) the most aggressive breast cancer subtype. We found that miR-29b-1-5p 
was downregulated in human TNBC tissues and cell lines. To assess whether miR-
29b-1-5p correlated with TNBC regenerative potential, we evaluated cancer stem 
cell enrichment in our TNBC cell lines, and found that only MDA-MB-231 and BT-20 
produced primary, secondary and tertiary mammospheres, which were progressively 
enriched in OCT4, NANOG and SOX2 stemness genes. MiR-29b-1-5p expression 
inversely correlated with mammosphere stemness potential, and miR-29b-1 ectopic 
overexpression decreased TNBC cell growth, self-renewal, migration, invasiveness 
and paclitaxel resistance repressing WNT/βcatenin and AKT signaling pathways and 
stemness regulators. We identified SPINDLIN1 (SPIN1) among predicted miR-29b-
1-5p targets. Consistently, SPIN1 was overexpressed in most TNBC tissues and cell 
lines and negatively correlated with miR-29b-1-5p. Target site inhibition showed that 
SPIN1 seems to be directly controlled by miR-29b-1-5p. Silencing SPIN1 mirrored 
the effects triggered by miR-29b-1 overexpression, whereas SPIN1 rescue by 
SPIN1miScript protector, determined the reversal of the molecular effects produced 
by the mimic-miR-29b-1-5p. Overall, we show that miR-29b-1 deregulation impacts 
on multiple oncogenic features of TNBC cells and their renewal potential, acting, at 
least partly, through SPIN1, and suggest that both these factors should be evaluated 
as new possible therapeutic targets against TNBC.
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INTRODUCTION
Despite improved diagnostic skills and 
breakthroughs in effective treatment, breast cancer 
continues to be the leading cause of cancer deaths among 
women worldwide, with breast cancer incidence and 
death rates generally increasing with age [1]. Human 
triple-negative breast cancer (TNBC), which accounts 
for approximately 10–20% of all breast tumors, refers 
to forms that do not express estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER2) [2]. These forms present a 
very difficult therapeutic challenge as are characterized 
by high heterogeneity, a particularly aggressive nature 
and by the lack of targeted therapies [3]. Although the 
metastatic potential in TNBC is similar to that of other 
breast cancer subtypes, these tumors exhibit the highest 
therapy resistance and the poorest prognosis, and are 
associated with a shorter median time to relapse and 
death [4]. Thus, achieving a better understanding of the 
molecular mechanisms underlying TNBC is a crucial need 
to identify novel diagnostic/prognostic biomarkers and to 
develop novel therapeutic strategies. In particular, it is 
recognized that, to be effective, therapeutic strategies need 
to eradicate cancer stem cells (CSCs), a subpopulation of 
cancer cells that are thought to be at the root of cancer [5]. 
Indeed, CSCs seem to be the cause of cancer initiation, 
growth and development, the source for tissue renewal 
and malignant potential, the crucial component leading to 
tumor recurrence, therapy resistance, and metastasis [6].
Recently it has been shown that in human cancers 
the malignant potential also depends on a widespread 
deregulation of microRNAs (miRNAs, miRs) [7], a class 
of small non-coding RNAs that regulate gene expression 
post-transcriptionally and may function as a novel class 
of oncogenes and tumor suppressor genes [8]. Several 
studies have shown that miRNAs are involved in the self-
renewal and fate decisions of stem cells and that in CSCs 
these mechanisms are altered [9, 10]. Dysregulation of 
miRNAs has been reported in human cancers including 
breast cancer [11, 12]. Mir-29b is known to regulate a 
number of important genes that mediate carcinogenesis 
and tumor development in breast cancer [13]. Moreover, 
in breast cancer patients miR-29b is shown to act as tumor 
suppressor and low miR-29b expression in primary tumor 
tissues is a prognostic factor for breast cancer patients [14].
However, although miR-29b is considered to be 
a tumor suppressor in multiple types of cancers [15, 16], 
very few studies have investigated the effects of miR-29b-
1-5p in human breast cancer cells and none in TNBC cells. 
This is a particularly important aspect of our research, 
because it is known that in the big family of miR-29 each 
member plays often opposing functions. In particular, it has 
been reported that in mouse breast cancer cells, miR-29b 
inhibits metastasis by targeting a network of pro-metastatic 
regulators involved in angiogenesis, collagen remodeling 
and proteolysis [13], whereas in the metastatic human 
breast cancer cell line MDA-MB-231, aberrant expression 
of miR-29b can contribute to migration and invasion [17]. 
Moreover, in many malignant cells miR-29b was proved 
to be an epi-miRNA that targets DNA methyltransferases 
(DNMTs) and/or regulates DNA demethylation pathway 
members, leading to the downregulation of global DNA 
methylation [18]. In addition, in human ER+PR+ breast 
cancer cells, the downregulation of miR-29 members 
increases mammosphere formation in vitro and tumor 
initiating capability in vivo [19].
In our previous studies on osteosarcoma (OS), a 
tumor in which the miRNA-29 family members (miR-
29a/b/c; miR-29s) are often deregulated [20, 21], we 
found that ectopic expression of miR-29b-1 was able to 
suppress the stemness properties of the 3AB-OS cell line 
[22], a novel CSC line by us produced [23], suggesting 
that miR-29b-1 could be a novel therapeutic agent against 
OS. This background led us to study the role of miR-29b-1 
in TNBC cells.
Here we demonstrated that miR-29b-1-5p expression 
was significantly downregulated in most TNBC tissues 
and in all the examined cell lines. MDA-MB-231 and 
BT-20 cells can produce primary, secondary and tertiary 
mammospheres which possess great regenerative properties 
and high levels of stemness genes (OCT4, SOX2 and 
NANOG). In MDA-MB-231 and BT-20 cells, miR-29b-1 
ectopic expression strongly decreased cell proliferation, 
viability, self-renewal, migration and invasiveness, also 
increasing sensitivity to paclitaxel. We found that SPIN1 
seems to be directly controlled by miR-29b-1-5p and 
that SPIN1 silencing mirrored the effects of miR-29b-1 
overexpression. Thus, in TNBC cells the simultaneous 
miR-29b-1-5p down regulation and SPIN1 up-regulation 
can potentially be associated with TNBC malignancy and 
may be a potential new druggable target for TNBC.
RESULTS
MiRNA-29b-1-5p is downregulated in TNBC 
tissues and cell lines
The expression of miR-29b-1-5p in human triple-
negative breast cancer (TNBC) tissues and cell lines, was 
evaluated by quantitative RT-PCR (qRT-PCR). In TNBC 
tissues the analysis was carried out in 21 formalin-fixed, 
paraffin-embedded (FFPE) cancerous tissues, compared 
to 6 normal human mammary tissues; in TNBC cell lines 
the analysis was performed in MDA-MB-231, BT-20, 
HCC1395 and MDA-MB-468 cells compared to HMEC, 
a normal human mammary epithelial cell line. We found 
that miR-29b-1-5p expression was downregulated in 
fifteen of the twenty-one TNBC tissues (71.4%); a potent 
upregulation was observed in two of the twenty-one 
tissues (9.5%); no variations were observed in the other 
four TNBC tissues (Figure 1A). The analysis of miR-29b-
1-5p expression in all the four TNBC cell lines studies 
evidenced its strong downregulation (Figure 1B). These 
Oncotarget3www.impactjournals.com/oncotarget
findings suggested that miR-29b-1-5p down-regulation 
could play a role in TNBC development.
MiRNA-29b-1-5p and TNBC stem cell features
To assess whether miR-29b-1-5p expression 
correlated with TNBC regenerative potential, we first 
evaluated the enrichment in CSCs of the TNBC cell lines. 
We evaluated their “mammosphere forming ability”, an 
assay which tests the ability to form organoid spheres 
in serum free medium in low adherences dishes, which 
is a recognized property of cells which contain CSCs 
[24] and have self-renewal potential [25]. In particular, 
the TNBC cell lines above described were tested for 
their ability to produce primary, secondary and tertiary 
mammospheres. Only MDA-MB-231 and BT-20 cell 
Figure 1: MiR-29b-1-5p expression in TNBC tissues and cell lines, and mammosphere formation ability of TNBC cell 
lines. (A) miR-29b-1-5p expression was determined in 21 TNBC specimens (T) compared to 6 controls (N). (B) miR-29b-1-5p expression 
was determined in four human TNBC cell lines compared to normal human mammary epithelial cell line (HMEC). Data represent the 
mean with standard deviation (n = 3 independent experiments carried out in triplicate); NS, not significant; * P < 0.05; ** P < 0.01; *** P 
< 0.001. (C) Phase contrast microscopy of adherent cells and of primary (M1), secondary (M2) and tertiary (M3) mammospheres formed 
by TNBC cell lines. The scale bar represents 100 μm. (D) Bar graph represents the sphere forming efficiency (SFE) calculated for each 
passage as described in Materials and Methods. Data represent the mean with standard deviation (n = 3 independent experiments carried out 
in quadruplicate); * P < 0.05; ** P < 0.01. (E and F) Real-time RT-PCR analysis of stemness genes in M1, M2 and M3 mammospheres by 
MDA-MB-231 and BT-20 cells, respectively. Data represent the mean with standard deviation (n = 3 independent experiments carried out 
in triplicate); * P < 0.05; ** P < 0.01 as compared to adherent cells. (G) miR-29b-1-5p expression in tertiary mammospheres (M3) formed 
by both MDA-MB-231 and BT-20 cell lines compared to adherent cells. Data represent the mean with standard deviation (n = 3 independent 
experiments carried out in triplicate); ***, P < 0.001.
Oncotarget4www.impactjournals.com/oncotarget
lines were capable of generating mammospheres until the 
tertiary stage, whereas the HCC-1395 cell line failed to 
generate tertiary spheres and MDA-MB-468 cell line were 
even incapable of generating secondary mammospheres, 
only producing some unstable aggregations (Figure 1C 
and 1D), thus suggesting that MDA-MB-231 and BT-20 
cell lines possess a regenerative capacity greater than the 
other TNBC cell lines. Because the regenerative capacity 
depends on stemness properties, we also evaluated 
the relative expression of stemness genes at the three 
mammosphere stages. With respect to the adherent cells, 
from the primary to the tertiary mammosphere stages, in 
both, MDA-MB-231 cells and BT-20 cell we observed a 
progressive enrichment in the OCT4, NANOG and SOX2 
stemness genes (Figure 1E and 1F). Interestingly, in 
tertiary mammospheres compared to adherent cells, miR-
29b-1-5p expression dramatically decreased (Figure 1G), 
suggesting its inverse correlation with stemness.
Ectopic overexpression of miR-29b-1 in MDA-
MB-231 cells and BT-20 cells
To determine the role of miR-29b-1 in TNBC cells, 
MDA-MB-231 cells (Figure 2A) and BT-20 cells (Figure 
2B) were stably transfected with either empty vector 
(control cells) or vector containing pre-miR-29b-1 (miR-
29b-1 cells) and compared to untransfected cells. Phase 
contrast microscopy (left panels) fluorescence microscopy 
(middle panels) and flow cytometry (right panels) of the 
green fluorescent protein (GFP) show, in both control and 
miR-29b-1 cells, a strong positivity for GFP (>92%), which 
demonstrates a high transfection efficiency. QRT-PCR 
assays (Figure 2C) evidences that, following pre-miR-
29b-1 transfection, miR-29b-1-5p levels were up-regulated 
in MDA-MB-231 and BT-20 cells, compared with both 
control and untransfected cells, by approximately 19-fold 
and 6.5-fold, respectively (Figure 2C).
MiR-29b-1 inhibited MDA-MB-231 and BT-20 
cell proliferation by perturbing cell cycle
To investigate the effects of miR-29b-1 
overexpression in MDA-MB-231 cells and BT-20 cells 
(Figure 3A), the cells were incubated for 0-96 h under 
cultural conditions, then, cell growth was analyzed by 
cell count, and cell viability by propidium iodide (PI) 
exclusion. MiR-29b-1 overexpression significantly 
decreased growth rate in both cell lines (left panels), 
showing decreased viability in MDA-MB-231 cells, but 
not in BT-20 cells (right panels). As during these studies 
Figure 2: Ectopic expression of miR-29b-1 in MDA-MB-231 and BT-20 cell lines. (A and B) Phase contrast and fluorescence 
microscopy of untransfected cells and cells stably transfected with either empty vector (control) or miR-29b-1 expressing vector (miR-
29b-1). The scale bar represents 100 μm. In flow cytofluorimetric analysis the untransfected cells were used as negative control. The 
analysis shows the density plots of forward scatter (FS; linear scale) vs FL1 channel (FL1 log scale). Images are representative of four 
independent experiments. (C) Real-time RT-PCR analysis, in both cell lines, of miR-29b-1-5p in untransfected cells, cells stably transfected 
with either empty vector (control) or miR-29b-1 expressing vector (miR-29b-1). Data represent the mean with standard deviation (n = 4 
independent experiments carried out in triplicate); NS, not significant; ** P < 0.01 as compared to untransfected cells.
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we never observed statistically significant differences 
(P>0.05) between untransfected cells and cells transfected 
with the empty vector, in subsequent experiments, cells 
transfected with the empty vector were then used as 
controls. Cell cycle analysis by flow cytometry evidenced 
that in MDA-MB-231 cells compared to control cells, 
(Figure 3B, top panel and 3C, left panel) miR-29b-1 
overexpression increased the percentage of cells at the sub-
G0-G1 and G2-M-phases by 11.1% and 2.2% respectively, 
whereas it decreased the percentage of cells at the G0-
G1 and S phases by 13.6% and 3.9% respectively. In BT-
20 cells (Figure 3B, bottom panel and 3C, right panel) 
miR-29b-1 overexpression increased the percentage of 
cells at the sub-G0-G1 and G2-M-phases by 6.6% and 
3.9% respectively, whereas at G0-G1 and S phases the 
percentage of cells decreased by 8.5% and 1.7%. Ectopic 
miR-29b-1 also increased the rate of polyploidy by 4.7% 
in MDA-MB-231 cells compared with control cells but not 
Figure 3: Effect of ectopic expression of miR-29b-1 on cell growth, viability, cell cycle distribution and apoptosis in 
MDA-MB-231 and BT-20 cell lines. (A) Cellular growth (left panels) and viability (right panels) in both cell lines (untransfected and 
transfected cells) were evaluated by cell counting and PI exclusion method, respectively. Data represent the mean with standard deviation 
(n = 3 independent experiments carried out in triplicate); NS, not significant; * P < 0.05, ** P < 0.01 as compared to untransfected cells. 
(B) Histogram plots of flow cytometry analysis performed in both MDA-MB-231 (top panels) and BT-20 (bottom panels) transfected cells 
(control and miR-29b-1). (C) Cell cycle distribution determined by flow cytometry. Data represent the mean with standard deviation (n = 3 
independent experiments carried out in triplicate); NS, not significant; * P < 0.05, ** P < 0.01 as compared to control cells. (D) Histogram 
plots of Annexin V flow cytometry analysis performed in both MDA-MB-231 (left panels) and BT-20 (right panels) transfected cells 
(control and miR-29b-1) are shown. Images are representative of four independent experiments. (E) Graph summarizing the percentage of 
Annexin V positive cells. Data represent the mean with standard deviation (n = 4 independent experiments carried out in triplicate); * P < 
0.05, ** P < 0.01 as compared to control cells.
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in BT-20 cells. Interestingly, the accumulation of the cells 
at the sub-G0/G1 phase and flow cytometry analysis of the 
Annexin V (Figure 3D and 3E) suggest that ectopic miR-
29b-1 expression could lead to apoptosis. Cytofluorimetric 
analysis of the proliferation marker Ki-67 (Figure 4A and 
4B) shows that by miR-29b-1 overexpression, both MDA-
MB-231 and BT-20 cells resulted to be less Ki-67-positive 
than control cells. In addition, RT-PCR analyses of the 
proliferative markers MKI67 and HIST4H4, show that 
miR-29b-1 markedly decreased their levels (Figure 4C).
Figure 4: Effect of miR-29b-1 overexpression on cell proliferation markers and self-renewal in MDA-MB-231 and BT-
20 cell lines. (A) Flow cytofluorimetric analysis in both transfected cell lines, of Ki-67 positive cells in comparison with isotype control. 
Density plots of side scatter (SS; linear scale) vs FL1 channel (FL1 log scale) are shown. Images are representative of four independent 
experiments. (B) Graph summarizing Ki-67 reactivity. Data represent the mean with standard deviation (n = 4 independent experiments 
carried out in triplicate); * P < 0.05, ** P < 0.01 as compared to control cells. (C) Real-time RT-PCR analysis of cell proliferation markers 
in both the transfected cell lines. Data represent the mean with standard deviation (n = 3 independent experiments carried out in triplicate); 
** P < 0.01 ***, P < 0.001 as compared to control cells. (D) Phase contrast and fluorescence microscopy and merge images of primary 
mammospheres from both the transfected cell lines after 10 days in culture. The scale bar represents 200 μm. Images are representative of 
four independent experiments. (E) Bar graphs represent the sphere forming efficiency (SFE) and size of mammospheres. Data represent 
the mean with standard deviation (n = 4 independent experiments carried out in triplicate); NS, not significant; * P < 0.05; ***, P < 0.001 
as compared to control cells. (F) Bar graph represents the sphere forming efficiency (SFE) calculated for each passage [primary (M1), 
secondary (M2) and tertiary (M3) mammospheres]. Data represent the mean with standard deviation (n = 4 independent experiments 
carried out in triplicate); * P < 0.05; **, P < 0.01.
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MiR-29b-1 overexpression markedly decreased 
self-renewal capacity of MDA-MB-231 and BT-
20 cells
To test whether, low/absent miR-29b-1 levels 
are necessary for self-renewal in MDA-MB-231 
and BT-20 cells, we studied the effect of miR-29b-1 
overexpression by mammosphere assay. By this assay, 
the number of the formed mammospheres reflects the 
quantity of cells capable of in vitro self-renewal (Sphere 
forming efficiency, SFE), whereas the mammosphere 
size measures the self-renewal capacity of each sphere-
generating cell [24]. Phase contrast and fluorescence 
microscopy (Figure 4D, top panel) show that MDA-
MB-231 control cells efficiently formed spheres whereas, 
following miR-29b-1 overexpression, they formed fewer 
primary mammospheres than control cells. Also BT20 
cells formed mammospheres (Figure 4D bottom panel), 
but they appeared smaller than these formed by MDA-
MB-231-mammospheres and their culture medium 
contained a great number of cells probably released by 
some loosely packed mammospheres. The same figure 
also shows that miR-29b-1 decreased their dimension.
In MDA-MB-231 cells the percentage of SFE of 
miR-29b-1 cells was about 64% lower than control cells 
(Figure 4E, top panel, left), whereas the mean diameter of 
miR-29b-1 spheres (bottom panel, left)) was about 22% 
smaller than in control spheres. In BT20 cells (Figure 
4E, top panel, right) the percentage of SFE of miR-29b-1 
compared to control cells did not vary, whereas the mean 
diameter of miR-29b-1 spheres (bottom panel, right) was 
about 21% smaller than in control spheres. This suggested 
that in both cell lines the self-renewal capacity of each 
miR-29b-1 cell-generating sphere was much lower than 
in control cells.
To further assess whether miR-29b-1 may control 
mammosphere self-renewal, primary mammospheres were 
dissociated into single cells and reseeded to analyze the 
ability to form secondary and tertiary mammospheres. 
We found, in both, MDA-MB-231 and BT-20 cells 
(Figure 4F, top and bottom panels) that the inhibition 
of mammosphere-formation determined by miR-29b-1 
overexpression was maintained also in the secondary 
and tertiary mammospheres. The evidence that at each 
mammosphere stage the relative self-renewal capacity 
increased, suggests a progressive enrichment in CSCs. 
Overall, these data reinforce the idea that miR-29b-1 may 
be involved in the control of growth and self-renewal 
capacity of MDA-MB-231 and BT-20 cells.
MiR-29b-1 overexpression strongly inhibited 
migration and invasion of MDA-MB-231 and 
BT-20 cells
In MDA-MB-231 cells wound healing assay (Figure 
5A, top panel and 5B, left panel) showed that, at 8 h and 
32 h after scratching, cells overexpressing miR-29b-1 
migrated more slowly than control cells. Indeed, after 32 
h, the wound area was almost recovered in control cells 
whereas in miR-29b-1 cells wound closure was 38% lower. 
Moreover, miR-29b-1 significantly decreased the invasive 
ability of MDA-MB-231 cells (Figure 5C, top panel), 
which was 34% lower than control cells. BT-20 cells 
(Figure 5A, bottom panel and 5B, right panel) evidenced 
a migration ability much lower than MDA-MB-231 cells, 
as at 32 h, the scratch in control cells was very far from 
being repaired and miR-29b-1 overexpression furthermore 
lowered (about 10%) cell repairing capacity. Also the 
relative invasion ability of both MDA-MB-231 and BT-
20 was severely impaired by miR-29b-1 overexpression, 
as assessed through transwell invasion assay (Figure 5C, 
bottom panels).
In MDA-MB-231 and BT-20 cells paclitaxel 
enhances the perturbing effects induced on cell 
cycle by miR-29b-1 overexpression
To assess whether miR-29b-1 affects cell 
susceptibility to paclitaxel (one of the major drugs used 
for breast cancer chemotherapy), we treated MDA-
MB-231 and BT-20 miR-29b-1overexpressing cells and 
their relative controls with 50, 100 and 200 nM paclitaxel 
for 24h. In MDA-MB-231 cells (Figure 6A) analysis of 
relative cell number (left panel) shows that, in control 
cells, 50, 100 and 200 nM paclitaxel decrease cell growth 
by 13.7%, 33.4% and 37.3% respectively, whereas in 
cells overexpressing miR-29b-1 the decrease was 35.4%, 
62.6% and 67%, respectively. Analysis of cell viability 
by PI exclusion (right panel) shows that, in control cells 
the effect of paclitaxel was significant only at 200 nM 
which increased the percentage of PI positive cells from 
6% to 8.5%. MiR-29b-1 overexpression increased to 14% 
the percentage of PI positive cells, whereas 100 and 200 
nM paclitaxel increased this percentage to 19.4% and 
22.5% respectively. In BT-20 cells (Figure 6B), 50, 100 
and 200 nM paclitaxel decreased the growth of control 
cells by 21.3%, 36.1% and 49.1% respectively, whereas 
in miR-29b-1 cells these concentrations decreased the 
growth by 37.2%, 58.3% and 69.3% respectively (left 
panel). PI exclusion (right panel) shows that, in control 
cells 100 and 200 nM paclitaxel significantly increased 
the percentage of PI positive cells from 5.3% to 12.2% 
and 18.3%, respectively. In BT-20 cells overexpressing 
miR-29b-1 paclitaxel 50 nM and 100 nM increased the 
percentage of PI positive cells from 7.9% to 15.8% and 
25.6%, respectively. No further increases in cytotoxicity 
were observed with 200 nm paclitaxel. We also assessed 
whether paclitaxel induces changes on the perturbing 
activity of miR-29b-1 overexpression on cell cycle. 
Flow cytometry assay of DNA content shows that, in 
both MDA-MB-231 and BT-20 cells (Figure 6C and 
6D) paclitaxel markedly increased the percentage of 
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cells accumulated in the sub-G0/G1 and G2-M phases of 
cell cycle, and decreased those in G0/G1 and S phases. 
Overall, these results suggest that ectopic miR-29b-1 
expression sensitizes the cells to the effects of paclitaxel. 
Interestingly, the effects of paclitaxel were in keeping with 
the perturbing effects of miR-29b-1 on the cell cycle.
SPIN1 is under the control of miR-29b-1-5p
To identify potential miR-29b-1-5p targets, we 
used a bioinformatics approach through the MIRDB.org 
database. The MIRDB algorithm predicted a number of 
candidate target genes, listed in the Supplementary Table 
1, among which we focused on SPINDLIN1 (SPIN1), 
a histone code reader highly expressed in several types 
of tumors and strongly implicated in tumorigenesis and 
tumor growth [26]. Then, we chose to analyze, between 
the two putative miR binding sites on SPIN1 3'UTR 
identified by Targetscan 7.0 and microRNA.org., the one 
with the better score (Figure 7A). Eventually, we assessed 
whether SPIN1 could be involved in MDA-MB-231 and 
BT-20 cells tumorigenesis and invasivity and if it could 
be a miR-29b-1-5p target. Firstly, we evaluated the 
expression of SPIN1 in the human TNBC tissues and cell 
lines described above and characterized by miR-29b-1-
5p down regulation. QRT-PCR analysis showed that, in 
comparison with normal breast tissues, SPIN1 appears 
significantly up-regulated in 10 (47.6%) and down-
Figure 5: MiR-29b-1 overexpression reduces migration and invasion of MDA-MB-231 and BT-20 cell lines. (A) 
Representative phase contrast microscopy from the wound-healing assay. The scale bar represents 100 μm. (B) Quantification of the scratch 
wound-healing assay. The extent of wound closure was quantified by measuring the wound area compared to the initial wound area. Data 
represent the mean with standard deviation (n = 4 independent experiments carried out in triplicate); * P < 0.05; ** P < 0.01 ***, P < 0.001 
as compared to control cells. (C) Representative images from the transwell invasion assays. Invading cells were stained with Hoechst 33342 
(merged images). The scale bar represents 50 μm. Bar graph represents the number of invading cells per field. Data represent the mean with 
standard deviation (n = 4 independent experiments carried out in triplicate); * P < 0.05 as compared to control cells.
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regulated in 5 (23.8%) of the 21 TNBC specimens studied 
(Figure 7B) and the analysis of its correlation with miR-
29b-1-5p overexpression demonstrated that it is negatively 
correlated with SPIN1 expression (Figure 7C). We also 
showed that, in MDA-MB-231 and BT-20 cells compared 
to the normal human mammary epithelial cell line HMEC, 
SPIN1 was strongly upregulated (Figure 7D). Moreover, 
qRT-PCR and western blot analyses showed that miR-29b-
1-5p overexpression strongly impairs SPIN1 mRNA and 
protein levels (Figure 7E). Accordingly, in both cell lines 
the inhibition of endogenous miR-29b-1-5p by miR-29b-
1-5p-LNA (a miR-29b-1-5p inhibitor), compared to the 
negative control, resulted in the upregulation of SPIN1 
mRNA and protein (Figure 7F). These data suggest that 
miR-29b-1-5p can regulate SPIN1 at both mRNA and 
protein levels. Moreover, after transfection with either hsa-
miR-29b-1-5p mimic, or hsa-miR-29b-1-5p mimic plus 
negative control miScript target protector, or hsa-miR-29b-
1-5p mimic plus miScript target protector (Figure 7G), 
the levels of SPIN1 mRNA were strongly higher in cells 
transfected with hsa-miR-29b-1-5p mimic plus miScript 
target protector than in control cells (cells transfected with 
hsa-miR-29b-1-5p Mimic or hsa-miR-29b-1-5p Mimic 
plus Negative control miScript Target Protector). These 
results suggest that SPIN1 may be directly controlled by 
miR-29b-1-5p.
In MDA-MB-231 cells, silencing SPIN1 mirrored 
the miR-29b-1 overexpression
To explore the function of SPIN1 in TNBC cells, 
MDA-MB-231 cells (the most aggressive cell line within 
our panel) were stably transfected with either sh-SPIN1 
or sh-Ctrl. QRT-PCR and western blot analyses show 
that, compared to sh-Ctrl cells, in sh-SPIN1 cells, SPIN1 
levels profoundly lowered (Figure 8A). Then, using 
sh-SPIN1 cells compared to sh-Ctrl cells, we assessed 
cell proliferation, mammosphere-forming ability, 
migration/invasive ability and paclitaxel sensitivity. The 
results showed that (Figure 8B) sh-SPIN1 cells have 
a proliferative rate lower than sh-Ctrl cells (left panel), 
whereas their viability appeared unmodified (right panel). 
In addition, silencing SPIN1 led to a strong perturbation 
of the cell cycle with an increase of cell percentage in 
subG0-G1 phase, a significant decrease in G0-G1 and S 
phases and an increase in polyploidy rate (Figure 8C). 
These results were very similar to those already reported 
in Figure 3B (top panel) and 3C (left panel) for MDA-
MB-231 cells overexpressing miR-29b-1. Also for 
mammosphere formation, wound closure, cell invasivity 
and paclitaxel effects SPIN1 silencing mimicked the 
effects of miR-29b-1 overexpression. Indeed, SPIN1 
silencing strongly inhibited the ability to form primary, 
Figure 6: MiR-29b-1 overexpression increases sensitivity of MDA-MB-231 and BT-20 cell lines to paclitaxel. (A and 
B) Both the transfected cell lines were treated with paclitaxel (50, 100 and 200 nM) for 24 h. Relative cell number was determined by 
counting the cells and dividing the number of live cells arising from each treatment condition, with respect to the untreated control, 
multiplied hundred. Dead cells were evaluated using PI exclusion assay. Data represent the mean with standard deviation (n = 4 independent 
experiments carried out in triplicate); NS, not significant; * P < 0.05; ** P < 0.01 ***, P < 0.001. (C and D) Cell cycle distribution of both 
the transfected cell lines using flow cytometry. Data represent the mean with standard deviation (n = 4 independent experiments carried out 
in triplicate); NS, not significant; * P < 0.05 and ** P < 0.01.
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Figure 7: MiR-29b-1-5p targets SPIN1. (A) MiR-29b-1-5p predicted target site within SPIN1 3'UTR identified by TargetScan 
(top) and microRNA (bottom) online software. (B) SPIN1 expression was determined by real-time RT-PCR in 21 TNBC specimens (T) 
compared to 6 controls (N). Data represent the mean with standard deviation (n = 3 independent experiments carried out in triplicate); NS, 
not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. (C) The correlation between miR-29b-1-5p and SPIN1 mRNA expression in 21 
TNBC tissues was evaluated using Pearson’s correlation analysis. (D) SPIN1 expression in MDA-MB-231 and BT-20 cell lines compared 
to normal human mammary epithelial cell line (HMEC). Data represent the mean with standard deviation (n = 3 independent experiments 
carried out in triplicate); ** P < 0.01. (E) MDA-MB-231 and BT-20 cells stably transfected with either empty vector (control) or miR-
29b-1 expressing vector (miR-29b-1). SPIN1 mRNA and protein expression were determined by Real-time RT-PCR and Western blot 
analyses, respectively. The numbers below the blot panels indicate the fold change of SPIN1 levels with respect to control. Actin was used 
as loading control. Data represent the mean with standard deviation (n = 4 independent experiments carried out in triplicate); *** P < 0.001 
as compared to control cells. (F) MDA-MB-231 and BT-20 cells transfected with either LNA-inhibitor-Ctrl or LNA-miR-29b-1-5p. SPIN1 
mRNA and protein expression were determined by Real-time RT-PCR and Western blot analyses, respectively. The numbers below the 
blot panels indicate the fold change of SPIN1 levels with respect to LNA-inhibitor-Ctrl. Actin was used as loading control. Data represent 
the mean with standard deviation (n = 4 independent experiments carried out in triplicate); *** P < 0.001 as compared to LNA-inhibitor-
Ctrl cells. (G) MDA-MB-231 and BT-20 cells transfected with miR-29b-1-5p mimic alone, or co-transfected with miR-29b-1-5p mimic 
and negative control target protector or co-transfected with miR-29b-1-5p mimic and miScript target protector. SPIN1 mRNA expression 
was determined by Real-time RT-PCR after 72 h of transfection. Data represent the mean with standard deviation (n = 4 independent 
experiments carried out in triplicate); NS, not significant; ** P < 0.01 as compared to miR-29b-1-5p mimic cells.
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secondary and tertiary mammospheres (Figure 8D), thus 
suggesting that SPIN1 is involved in the control of self-
renewal capacity of these cells. Moreover, sh-SPIN1 cells 
migrated more slowly (Figure 8E) and were less invasive 
(Figure 8F) than sh-Ctrl cells. Finally, sh-SPIN1 MDA-
MB-231 cells were more responsive to paclitaxel treatment 
as shown by cell growth (Figure 8G), cell viability (Figure 
8H) and cell cycle (Figure 8I) analysis.
Together, these results suggest that SPIN1 silencing 
induces a phenotype similar to that produced by miR-29b-1 
overexpression also proposing that SPIN1 may be, at least 
in part, responsible for the effects triggered by miR-29b-1.
Figure 8: Effect of SPIN1 silencing in MDA-MB-231 cells. (A) Real-time RT-PCR and western blot analyses of MDA-MB-231 
cells stably transfected with either sh-Ctrl or sh-SPIN1. The numbers below the blot panels indicate the fold change of SPIN1 levels with 
respect to sh-Ctrl. Actin was used as loading control. Data represent the mean with standard deviation (n = 4 independent experiments 
carried out in triplicate); NS, not significant; *** P < 0.001 as compared to sh-Ctrl cells. (B) Cellular growth and viability in transfected 
cells (sh-Ctrl or sh-SPIN1). Data represent the mean with standard deviation (n = 4 independent experiments carried out in triplicate); 
NS, not significant; * P < 0.05, ** P < 0.01 as compared to sh-Ctrl cells. (C) Histograms reporting cell cycle distribution assessed by flow 
cytometry. Data represent the mean with standard deviation (n = 4 independent experiments carried out in triplicate); NS, not significant; 
* P < 0.05, ** P < 0.01 as compared to sh-Ctrl cells. (D) Bar graph represents the sphere forming efficiency (SFE) calculated by counting 
for each passage [primary (M1), secondary (M2) and tertiary (M3) mammospheres]. Data represent the mean with standard deviation (n 
= 4 independent experiments carried out in triplicate); ** P < 0.01; ***, P < 0.001. (E) Quantification of the scratch wound-healing assay. 
The extent of wound closure was quantified by measuring the wound area compared with the initial wound area. Data represent the mean 
with standard deviation (n = 4 independent experiments carried out in triplicate); ** P < 0.01 as compared to sh-Ctrl cells. (F) Bar graph 
of the invasion assay. Bars represents the mean number of invading cells per field. Data represent the mean with standard deviation (n = 4 
independent experiments carried out in triplicate); ** P < 0.01 as compared to sh-Ctrl cells. (G, H and I) Cell growth, cell viability and cell 
cycle distribution of transfected cells treated with paclitaxel (50, 100 and 200 nM) for 24 h. Data represent the mean with standard deviation 
(n = 4 independent experiments carried out in triplicate); NS, not significant; * P < 0.05; ** P < 0.01 and *** P < 0.001.
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In MDA-MB-231 and BT-20 cells miR-29b-1 
overexpression represses WNT/β-catenin and 
Akt signalling pathways through SPIN1
Wnt/β-catenin and AKT signaling have been found 
to be aberrantly activated and to play crucial roles in the 
development and progression of breast cancer [27]. To 
evaluate the effects of miR-29b-1 overexpression on these 
pathways and the possible role of SPIN1, we employed 
MDA-MB-231 and BT-20 TNBC cells in which either 
miR-29b-1 was up/down-regulated or SPIN1 expression 
was silenced.
QRT-PCR analysis (Figure 9A, left panel) showed 
that miR-29b-1 overexpression, compared to control cells, 
markedly decreased MYC levels whereas significantly 
increased PTEN levels. However miR-29b-1 did not 
change AKT1,2,3 and β-catenin (CTNNB1) levels. Western 
blot analysis (Figure 9A, right panel) confirmed the effects 
of miR-29b-1 on MYC and PTEN expression, whereas, in 
contrast to mRNA analysis, it evidenced lower β-catenin 
Figure 9: MiR-29b-1 represses Wnt/β-catenin and Akt signalling pathways through SPIN1 in TNBC cells. (A and B) 
Evaluation of mRNA and protein expression of Wnt/β-catenin, Akt pathway and stemness regulators in MDA-MB-231 and BT-20 cells 
stably transfected with empty vector (control) and miR-29b-1 expressing vector (miR-29b-1). Data represent the mean with standard 
deviation (n = 4 independent experiments carried out in triplicate); NS, not significant; * P < 0.05; ** P < 0.01 and *** P < 0.001 as 
compared to control cells. The numbers below the blot panels indicate the fold change of the signaling component levels with respect to 
control. Actin was used as loading control. (C and D) Evaluation of mRNA and protein expression of Wnt/β-catenin, Akt pathway and 
stemness regulators in MDA-MB-231 and BT-20 cells transfected with LNA-inhibitor-Ctrl and LNA-miR-29b-1-5p. Data represent the 
mean with standard deviation (n = 4 independent experiments carried out in triplicate); NS, not significant; * P < 0.05; ** P < 0.01 and *** 
P < 0.001 as compared to LNA-inhibitor-Ctrl cells. The numbers below the blot panels indicate the fold change of the signaling component 
levels with respect to LNA-inhibitor-Ctrl. Actin was used as loading control.
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and AKT1,2,3 levels. Also pAKT apparently lowered, but 
this probably depended on the AKT decrease. Since in 
several types of tumors, including breast cancer Wnt/β-
catenin and Akt- signaling pathways are implicated in the 
regulation of self-renewal of CSCs, and recently Akt has 
been identified as an upstream regulator of SOX2 protein 
in breast carcinoma [28], we also investigated whether 
miR-29b-1 affected the expression of OCT4, SOX2 and 
NANOG, key stemness genes. QRT-PCR and western blot 
analyses (Figure 9C) show that miR-29b-1 overexpression 
potently decreased the mRNA and protein levels of these 
genes (in particular SOX2). Overall, these results suggest 
that ectopic miR-29b-1 represses WNT/β-catenin and Akt 
signaling pathways. Thus, to assess if miR-29b-1 functions 
are required for the control of WNT/β-catenin and Akt 
signaling, we inhibited the endogenous miR-29b-1-5p by 
the miR-29b-1-5p-LNA inhibitor. The results show (Figure 
9B and 9D) that this inhibitor determined opposite effects 
to those obtained by miR-29b-1 overexpression (Figure 
9A and 9C). We also evaluated the effect of SPIN1-
silencing on WNT/β-catenin and Akt signaling. QRT/PCR 
and western blot analyses (Figure 10A and 10B) evidenced 
effects very similar to those determined by miR-29b-1 
overexpression. The only difference was that, in confront 
to that evidenced by miR-29b-1 overexpression (Figure 
9A) here western blot analysis evidences a lowering in 
pAKT levels stronger than in AKT levels, suggesting 
that SPIN1 could even control AKT phosphorylation. 
To further elucidate the role of SPIN1, we also analyzed 
whether, using SPIN1 miScript protector, the effects 
produced by the mimic-miR-29b-1-5p could be reversed. 
The results reported in Figure 10C demonstrate that SPIN1 
rescue determines the reversal of the molecular effects 
produced by the mimic-miR-29b-1-5p on the expression 
of genes (OCT4, SOX2, NANOG, MYC, PTEN, CXCR4 
and VEGFA) involved in the cell functions here analyzed.
Taken together, these data suggest that miR-29b-1-
5p by downregulating SPIN1 inhibits both WNT and Akt 
signaling pathways. This could contribute to the effects 
induced by miR-29b-1 on proliferation, self-renewal, 
migration, invasion and chemosensitivity in TNBC cells.
Figure 10: SPIN1 silencing represses WNT/β-catenin, Akt signaling pathways and stemness regulators in MDA-
MB-231 cells. (A) MDA-MB-231 cells stably transfected with either sh-Ctrl or sh-SPIN1. Real-time RT-PCR analysis of Wnt/β-catenin, 
Akt pathway components and stemness genes. Data represent the mean with standard deviation (n = 4 independent experiments carried 
out in triplicate); NS, not significant; * P < 0.05 and ** P < 0.01 as compared to sh-Ctrl. (B) Western blot analysis of Wnt/β-catenin and 
Akt pathway components and stemness proteins. The numbers below the blot panels indicate the fold change of the signaling component 
levels with respect to sh-Ctrl. Actin was used as loading control. (C) MDA-MB-231 cells transfected with miR-29b-1-5p mimic alone, or 
co-transfected with miR-29b-1-5p mimic and negative control target protector or co-transfected with miR-29b-1-5p mimic and miScript 
target protector. mRNAs expression was determined by Real-time RT-PCR after 72 h of transfection. Data represent the mean with standard 
deviation (n = 4 independent experiments carried out in triplicate); NS, not significant; * P < 0.05 and ** P < 0.01 as compared to miR-
29b-1-5p mimic cells.
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DISCUSSION
TNBC, is the most aggressive breast cancer subtype 
with a high propensity for metastasis and a poor prognosis 
[2]. Moreover, as the molecular profile of this cancer 
makes it unresponsive to hormonal treatment, it lacks a 
targeted therapy and the patients are more susceptible to 
relapse thus aggravating the prognosis [29, 30]. Although 
many effective options have been developed for treating 
breast cancer, unfortunately TNBC remains a subtype 
that is difficult to treat. Therefore, the search for new 
prognostic/diagnostic biomarkers and therapeutic targets 
is an urgent and imperative occurrence.
MiRNAs are small non-coding endogenous RNAs 
(around 22–25 nucleotides in length), involved in the 
regulation of gene expression [31, 32]. Since their 
discovery, a plethora of miRNAs have been identified to be 
involved in the gene silencing in cancer. A lot of research 
has shed light on miRNA functions showing that they 
can act as either oncogenes or tumor suppressor genes in 
breast cancer and more specifically in TNBC [33, 34, 35], 
even suggesting that they could be therapeutic targets [36]. 
However, although various mechanisms underlying both 
miRNA biogenesis and normal or deregulated expression 
have been extensively described [37], many causes leading 
to their abnormal expression in cancer remain largely 
ununderstood and are becoming an emerging theme in 
cancer research.
It has been demonstrated that the miR-29 family 
might function as a tumor suppressor and that expression 
of these miRNAs inhibits cell proliferation, promotes 
apoptosis of cancer cells, and suppresses tumorigenicity 
by targeting multiple oncogenes [38, 39]. Loss or 
downregulation of these miRNAs have been correlated 
with a higher-risk to develop several cancers including 
chronic lymphocytic leukemia, lung cancer, invasive 
breast cancer, cholangiocarcinoma [11].
MiR-29 family consists of four closely related 
members (miR-29a, miR-29b-1, miR-29b-2 and miR-
29c). However, albeit the miR-29 family members share 
a common seed region sequence (thus predicting that 
they target overlapping sets of genes), they frequently 
exhibit differential regulation and different subcellular 
distribution, suggesting different functional importance 
[40]. Dysregulation of miR-29 family has been reported 
in various cancers including breast cancers [15, 16, 
34, 41, 42]. MiR-29b has been reported to have many 
targets and to regulate ECM protein expression and 
tumor microenvironment. Enrichment of miR-29b has 
been found in luminal breast cancers where it inhibits 
metastasis by targeting a network of pro-metastatic 
regulators involved in angiogenesis, collagen remodeling 
and proteolysis as VEGFA, PDGF, MMP9, indirectly 
affecting differentiation and epithelial plasticity, with 
loss of miR-29b increasing metastasis and promoting a 
mesenchymal phenotype. Moreover, in human luminal 
breast cancer, GATA3 - which works by regulating 
miRNA-29b expression - emerged as a strong predictor of 
clinical outcome [13].
Anyhow, to our knowledge, to date, the functional 
expression and the role of miR-29b-1-5p in breast cancer, 
particularly in TNBC cancer, have not yet been elucidated.
Here we evaluated miR-29b-1-5p expression in 
human TNBC specimens and cell lines, employing both 
human TNBC FFPE tissues and TNBC cell lines. We have 
found that miR-29b-1-5p expression -compared to normal 
conditions- was significantly down-regulated. This solidly 
suggested that miR-29b-1-5p downregulation could play a 
role in TNBC development.
It is well known that cancers are diseases driven 
by CSCs that are responsible for poor clinical outcome, 
because they are the cause of reduced sensitivity to 
therapies, tumor regrowth, metastatic spread and 
morbidity and mortality of patients. Indeed, most tumors 
recur after an apparently successful eradication, probably 
since CSCs survive and restore tumor growth [43]. Here, 
we evaluated the enrichment in CSCs of the TNBC cell 
lines, by their ability to produce primary, secondary and 
tertiary mammospheres. We demonstrated that MDA-
MB-231 and BT-20 cells possess a regenerative capacity 
greater than other TNBC cells within our panel as they 
were the only capable of generating mammospheres until 
the tertiary stage. We also evaluated in them the expression 
of OCT4, NANOG and SOX2 -stemness genes which 
can control the regenerative capacity of the cells [44]- 
showing that, compared to the adherent cells, from the 
primary to the tertiary mammospheres stages, there was a 
progressive enrichment in the expression of these genes. 
Similarly to the tumors from which derive, TNBC cells are 
characterized by a strong heterogeneity at the genetic and 
molecular levels, which affects their phenotypes such as 
aggressiveness, metastatic ability and response to drugs, 
[45]. Such high rate of heterogeneity is likely to underlie 
the different mammosphere-forming ability observed in 
our cell lines.
Interestingly, in tertiary mammospheres we also 
observed a sharp decrease of miR-29b-1-5p expression 
with an inverse correlation with stemness. Thus, to 
understand the role of miR-29b-1 in TNBC cells, it was 
ectopically overexpressed in MDA-MB-231 and BT-20 
cells. We demonstrated that this overexpression potently 
decreased cell growth and viability, and strongly perturbed 
cell cycle. Moreover, ectopic miR-29b-1 markedly 
decreased self-renewal capacity of the cells even inhibiting 
their migration and invasive properties.
Aberrant expression of miRNAs has been associated 
with cancer chemoresistance, including resistance to 
paclitaxel [46] an anticancer drug belonging to the class 
of taxanes, which is a front-line chemotherapeutic agent 
for treating breast cancer [47]. Recently, it has been 
observed that in breast cancer cells miR-16 overexpression 
promoted Taxol-induced cytotoxicity and it has been 
suggested that miR-16 overexpression could be a strategy 
to overcome Taxol resistance in breast cancer [48].
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In this study we analyzed the effects of paclitaxel on 
MDA-MB-231 and BT-20 cells in which miR-29b-1 was 
either downregulated or was ectopically overexpressed. 
We observed that, after miR-29b-1 overexpression, 
paclitaxel effects were more potent than in cells in which 
miR-29b-1 was downregulated. Moreover, the effects 
of paclitaxel on cell cycle were in keeping with the 
perturbing effects induced by miR-29b-1 overexpression.
Searching putative miR-29b-1-5p targets we have 
found an algorithm predicting SPIN1 as potential target 
gene. It is known that SPIN1 is a histone code reader 
highly expressed in several types of cancers and strongly 
implicated in tumorigenesis and tumor growth [26, 49]. Its 
expression is upregulated in clinical tumor specimens and 
its ectopic expression promotes cancer cell proliferation 
through activation of WNT/β-catenin signaling [49]. 
We have shown that, in most TNBC specimens studied, 
SPIN1 appeared significantly upregulated and negatively 
correlated with miR-29b-1-5p expression. We also found 
a strong SPIN1 expression in both MDA-MB-231 and BT-
20 cells, which was remarkably reduced following ectopic 
miR-29b-1-5p overexpression. Conversely, inhibiting 
endogenous miR-29b-1-5p, resulted in the upregulation 
of SPIN1 mRNA and protein, according to the fact that 
miR-29b-1-5p and SPIN1 show an inverse correlation. In 
addition, using miScript target protector for SPIN1, our 
results suggested that SPIN1 may be directly controlled 
by miR-29b-1-5p. Moreover, in MDA-MB-231 cells, 
cell growth, viability, self-renewal, responsiveness to 
paclitaxel, migration and invasion, similarly changed by 
either miR-29b-1 overexpression or SPIN1-silencing. 
Overall, these results suggest that miR-29b-1-5p could 
directly control SPIN1 and that it could exert its effects by 
keeping SPIN1 downregulated.
As Wnt/β-catenin and AKT signalling have been 
found to be aberrantly activated and to play crucial 
roles in the development and progression of breast 
cancer [27, 50, 51], we also analysed the effects of miR-
29b-1 overexpression and the possible role of SPIN1 on 
these pathways. We have found that, upon miR-29b-1 
upregulation, the Wnt and Akt signaling pathways deeply 
fell in MDA-MB-231 and BT-20 cells. Moreover, miR-
29b-1 overexpression markedly decreased MYC levels 
also lowering the expression of the key stemness genes 
OCT4, SOX2 and NANOG. Conversely, the inhibition of 
miR-29b-1-5p produced opposite effects. It is interesting 
to note that in TNBC patients MYC expression has 
been found disproportionally elevated [52]. In addition, 
it has been reported that miR-29b-1/mir-29a promoter 
sequence is regulated by MYC, contributing to mir-
29 downregulation in human malignancies [53]. We 
also showed that SPIN1-silencing decreased both the 
expression of the key stemness genes and MYC levels, 
thus mirroring the effects determined by miR-29b-1 
overexpression. Moreover, using SPIN1 miScript 
protector, we demonstrated that SPIN1 rescue reversed the 
molecular effects produced by the mimic-miR-29b-1-5p 
on the expression of genes (OCT4, SOX2, NANOG, MYC, 
PTEN, CXCR4 and VEGFA) involved in the cell functions 
analysed. These results are particularly intriguing as 
it is known that in samples of breast cancer patients 
VEGF mRNA levels are correlated with CXCR4 mRNA 
levels, and that the CXCR4/CXCL12 signaling axis can 
induce angiogenesis and tumor progression by increasing 
expression of VEGF through the activation of PI3K/Akt 
pathway [54]. In conclusion, the results show that miR-
29b-1-5p inhibits both WNT and Akt signaling pathways 
by downregulating SPIN1 and suggest that miR-29b-1-5p, 
through SPIN1, might regulate the expression of MYC, 
CXCR4 and VEGFA counteracting their contribution to 
tumorigenesis.
Overall, our data show that miR-29b-1-5p 
deregulation impacts on multiple oncogenic features of 
TNBC cells and their renewal potential, acting through 
SPIN1 action and suggest that both these factors should 
be further evaluated as new possible therapeutic targets 
against TNBC.
MATERIALS AND METHODS
Tissue samples
Twenty-six breast tissue samples were collected 
in this study, including six normal breast tissues as 
control and twenty-one specimens diagnosed as TNBC 
(Supplementary Table 2). The specimens were obtained 
during surgery and were formalin fixed and embedded in 
paraffin (FFPE) using standard methods. Apart from T16 
that was a recurrence case, none of the patients included in 
the present study had received chemotherapy or radiation 
therapy prior to the study, and their complete clinical data 
were available, including age, histologic type, lymph node 
status, tumor size, stage, local relapse, distant metastatic 
relapse, ER status, PR status, and HER2 status. Histologic 
type was based on the TNM staging system, and the 
types were reclassified according to WHO classification 
and tumor stage (American Joint Committee on Cancer 
classification). The procedure for collecting and using 
the tissue samples was approved by the University of 
Malta, Research Ethical Committee, in accordance with 
the ethical standards as established in the Declaration of 
Helsinki.
RNA-isolation and real-time RT-PCR for 
detection of miR-29b-1-5p and SPIN1 in FFPE 
samples
Total RNA was isolated from FFPE tissues (five 
sections of 10 μm in thickness) using the RNA isolation 
kit FFPE (300115, Exiqon A/S, Vedbaek, Denmark) 
according to the manufacturer's instructions. All samples 
were analyzed on a Nanodrop 2000 instrument (Thermo 
Fisher Scientific, Waltham, USA).
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For miR-29b-1-5p detection, cDNA samples 
were made out 40 ng of total RNA using the miRCURY 
LNA™ Universal RT microRNA PCR Universal cDNA 
Synthesis kit II (203301, Exiqon A/S) according to the 
manufacturer’s recommendations. Afterward, real-time 
PCR was performed using 4μL of cDNA product, hsa-
miR-29b-1-5p LNA™ primers (204261, Exiqon A/S) 
and ExiLENT SYBR Green master mix (203403, Exiqon 
A/S). PCR was performed under the following conditions: 
95°C for 10 minutes, followed by 40 cycles of 95°C for 10 
seconds and 60°C for 1 minute.
For SPIN1 detection, 100 ng of total RNA was 
reverse transcribed by using the iScript™ cDNA Synthesis 
Kit (170-8890, Bio-Rad Laboratories S.r.l., Segrate, 
Milan, Italy), according to the manufacturer’s instructions. 
The resulting cDNAs were used for quantitative analysis 
by real-time PCR (qPCR) using the IQ SYBR Green 
Supermix (170-8882, Bio-Rad) and the QuantiTect 
primers (Qiagen, Milan, Italy) for SPIN1 (QT00024584). 
PCR cycling was performed as follows: 95°C for 10min; 
40 cycles of 95°C for 30 sec, 60°C for 60 sec, 72°C for 30 
sec; a final extension at 72°C for 5 min.
All real-time PCR reactions were performed in 
triplicate. To ensure that the RNA samples were not 
contaminated with genomic DNA, we included a no 
reverse transcriptase control (no RT) during each run of 
real-time RT-PCR. Furthermore, to check the accuracy of 
amplifications, we included a negative control in each run 
by eliminating the cDNA sample in the tube. Real-time 
PCR and data collection were performed on an IQ5 cycler 
instrument (Bio-Rad Laboratories S.r.l., Segrate, Milan, 
Italy); qPCR data were analyzed by IQ5 cycler software.
For miR-29b-1-5p detection, hsa-miR-24-3p 
(204260, Exiqon A/S), hsa-miR-26b-3p (204117, Exiqon 
A/S) and U6 snRNA (203907, Exiqon A/S) were used as 
control genes. Hsa-miR-24-3p (mean Ct = 21.71, S.D. = 
0.91) and hsa-miR-26b-3p (mean Ct = 26.83, S.D. = 0.93) 
showed the least variation between the 27 samples and 
were used as the endogenous reference. U6 was excluded 
because of too much variation (mean Ct = 22.75, S.D. = 
2.03) between the different samples. The relative amount 
of SPIN1 was normalized to GAPDH (QT01192646, 
Qiagen). Data were calculated using the comparative 2-
ΔΔCt method [55].
Cell lines
Human Mammary Epithelial Cells (HMECs) were 
purchased from Lonza (Walkersville, MD, USA) and 
grown according to the manufacturer’s instructions. 
Human TNBC cell lines MDA-MB-231 and MDA-
MB-468 were obtained from Interlab Cell Line Collection 
(ICLC, National Institute of Cancer Research, Genoa, 
Italy); BT20 and HCC-1395 cell lines from America Type 
Culture Collection (ATCC, Manassas, VA, USA). All cells 
were maintained according to supplier’s instructions and 
grown in an incubator at 37 °C in a humidified atmosphere 
containing 5% CO2.
Mammosphere formation assay
MDA-MB-231, BT20, HCC-1395 and MDA-
MB-468 cells were plated in 6-well ultra-low attachment 
plates (Corning Costar, Euroclone, Pero (MI), Italy) at 
appropriate density (5,000, 10,000, 15,000 and 20,000 
viable cells per ml respectively) in a stem cell medium 
to form mammospheres as previously described [56]. 
The stem cell medium was changed every 3 days, and 
cells were observed every day by an inverted phase 
contrast microscope equipped with a computer-imaging 
system (Leica DM IRB, Leica Microsystems Srl, Milan, 
Italy). After incubation for 10 days, the number of 
mammospheres that were larger than 50 μm in diameter 
(determined using the ImageJ software) was counted. For 
propagation, mammospheres were collected by gentle 
centrifugation, dissociated to single cells and then cultured 
to generate mammospheres of the next generation. Three 
passages were performed at intervals of 10 days. Sphere 
formation efficiency (SFE) at each passage was calculated 
by dividing the total number of spheres formed by the total 
number of live cells seeded, multiplied by hundred.
Plasmids and stable transfection
Vector construction for miR-29b-1 expression was 
previously described [22]. For stable transfection, MDA-
MB-231 and BT20 cells were plated in 6-well dishes until 
they reached 90% confluence and then transfected with 3 
μg of pCDHCMV-MCS-EF1-copGFP-T2A-PURO-miR-
29b-1 or empty vector as a control (hereafter indicated 
as miR-29b-1 cells and control cells, respectively), 
using TransIT-X2™ Dynamic Delivery System (MIR 
6003, Mirus Bio LLC, Madison, WI, USA) according to 
manufacturer’s instructions. Two days after transfections 
the cells were transferred in 100 mm dishes in selective 
medium containing 0.5 μg/ml puromycin (sc-108071, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA); 
the medium was replaced every 3-4 days. A plate of 
untransfected cells was used as a control for the selection. 
To assess transfection efficiency, green fluorescent protein 
(GFP) expressing cells were analyzed by fluorescence 
microscopy and flow cytometry as described previously 
[22].
For SPIN1-knockdown, MDA-MB-231 cells were 
allowed to grow till 90% confluency and then transfected 
with 2 μg of SPIN1 shRNA plasmid (sc-92696-SH, Santa 
Cruz Biotechnology) or Ctrl shRNA plasmid-A (sc-
108060, Santa Cruz Biotechnology) using TransIT-X2™ 
Dynamic Delivery System (Mirus Bio LLC) according 
to manufacturer’s instructions. For selection of stably 
transfected cells, we proceeded with puromycin selection 
as described above.
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Transient transfection
Both MDA-MB-231 and BT-20 cell lines were 
allowed to grow till 90% confluence and then transfected 
with a locked nucleic acid (LNA) probe containing a 
sequence specific antisense oligonucleotide targeting has-
miR-29b-1-5p, miRCURY LNA™ miR-29b-1-5p Power 
Inhibitor (50 nM, 427008-8, Exiqon A/S). Transfection 
was performed using TransIT-X2™ Dynamic Delivery 
System (Mirus Bio LLC) according to manufacturer’s 
instructions. A scrambled miRNA sequence, miRCURY 
LNA™ Power Inhibitor Control (50 nM, 199020-00, 
Exiqon A/S) served as a negative control. Cells were 
examined for each experiment 72 h after transfection.
Cell proliferation, viability, apoptosis, Ki-67 
expression and cell cycle analysis
Cellular growth and viability were evaluated by 
trypan blue (TB) exclusion assay as previously described 
[57]. Cell viability was also evaluated by propidium iodide 
(PI) exclusion test using flow cytometry assay. Similar to 
TB, PI has the ability to penetrate into cells that have lost 
plasma membrane integrity (dead cells) and to complex 
with DNA [58]. Briefly, cells were resuspended in 1 ml 
of PBS. PI (P4170, Sigma-Aldrich S.r.l., Milan, Italy) 
was added at 2 μg/ml for dead cell exclusion. Cells were 
incubated with the dye for at least 10 min at 4°C in the 
dark and submitted to flow cytometric analysis.
Apoptosis was evaluated using Annexin V-PE-Cy5 
Detection Kit (KA0718, Abnova Corporation, Taipei 
City, Taiwan) according to manufacturer’s instructions. 
Briefly, cells were trypsinized, centrifuged and washed 
once with serum-containing media before incubation 
with Annexin V-PE-Cy5. After another centrifugation, 
cells were resuspended in 1X Annexin V binding buffer 
at a concentration of 5 x 105 cells/500μl. Cell suspensions 
were incubated with 5 μl of Annexin V-PE-Cy5 for 5 min 
at a room temperature in the dark. Unstained cells were 
used as negative control. Analysis was performed by flow 
cytometry.
Flow cytometric analysis of Ki-67 and cell cycle 
were performed as previously reported [22]
All flow cytometric analyses were performed by a 
COULTER EPICS XL (Beckman Coulter S.r.l., Cassina 
De Pecchi, Milan, Italy) equipped with a blue argon 
laser (488 nm). PI fluorescence was measured in the FL3 
channel using a 620-nm BP filter and PE-Cy5 fluorescence 
was measured in the FL4 channel using a 675 nm BP filter. 
At least 1 x 104 events were acquired. Data were analyzed 
by Expo 32 software (Beckman Coulter).
In vitro scratch and invasion assays
MDA-MB-231 and BT-20 cells were seeded in 
6-well plates at a density of 1 x 106 cells/well in culture 
medium and grown to confluence. Then, cells were starved 
for 24 hours, and scraped with a 200-μl pipette tip to 
scratch the confluent cell monolayer. Culture medium was 
replaced with medium containing 0.1% FBS to minimize 
cell proliferation. Images of the wound area were captured 
by microscope (100x magnification) at the indicated time 
points. The extent of wound closure was determined by 
measuring through with the ImageJ software the area of 
cells that migrated into the wound and then dividing by 
the total area of wound.
Invasion assays were performed using 6-well 
invasion chamber system (Corning, Euroclone). MDA-
MB-231 and BT-20 cells were seeded in the upper chamber 
at 1.5 x 105 cells/well in culture medium serum-free. Culture 
medium containing 10% FBS (used as a chemoattractant) 
was placed in the bottom well. After 48 h, non migratory 
cells in the upper chamber were removed with a cotton-tip 
applicator, while invaded cells were counted and imaged 
by microscope after staining with Hoechst 33342 (2.5μg/
ml, B2261, Sigma-Aldrich). The number of invading cells 
was determined by counting five high-powered fields (200x 
magnification) on each membrane.
Paclitaxel treatment
Paclitaxel was purchased from Sigma (T1912, 
Sigma-Aldrich) and dissolved in dimethyl sulfoxide as 
previously reported [59]. Both MDA-MB-231 and BT-20 
cells were cultured to 150,000 cells/well in 6 well plates 
(Corning Costar, Euroclone) in culture medium. After 24 
h cells were treated with 50, 100 and 200 nM of paclitaxel 
for 24 h. Cellular growth, cell viability and cell cycle 
phase distribution were evaluated as described above.
Bioinformatic prediction of miRNA targets
Predicted has-miR-29b-1-5p target genes were 
obtained using MIRDB database (http://mirdb.org). All the 
targets were predicted by the bioinformatics tool, MirTarget 
(developed by analyzing thousands of miRNA-target 
interactions from high-throughput sequencing experiments).
After selecting SPIN1 as predicted target of hsa-
miR-29b-1-5p, the two target sites of SPIN1 3'UTR, 
predicted by MIRDB, were searched by the two widely 
used miRNA target prediction programs - Targetscan 7.0 
(http://www.targetscan.org) and microRNA.org (http://
www.microrna.org).
Target protector analysis
The miScript Target Protector for the miR-29b-1-5p 
binding site in the 3'UTR of SPIN1 mRNA was obtained 
from Qiagen (target binding site sequence provided: 5'-AA
AUCACAGUUACUUCUAAACCAGAUUUCA-3'; 
MTP0077240). The miScript Target Protector is single-
stranded, modified RNA that specially interferes with 
the interaction of a miRNA with a single target, while 
leaving the regulation of other targets of the same miRNA 
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unaffected. miRCURY LNA™ miR-29b-1-5p Mimic (25 
nM; 470851-001; Exiqon A/S) was transfected alone or 
co-transfected with miScript Target Protector (25 nM) 
into MDA-MB-231 and BT-20 cells according to the 
manufacturer's protocol. miRCURY LNA™ miR-29b-1-
5p Mimic and Negative Control Target Protector (25 nM; 
MTP0000002; Qiagen) designed not to bind the mRNA of 
mammals were co-transfected into TNBC cell lines as a 
negative control. After 72 h of transfection, the total RNA 
was isolated and the mRNA expression levels of SPIN1 
were measured by real-time RT-PCR.
RNA extraction and real-time RT-PCR for cell 
samples
Total RNA extraction, cDNA synthesis and real-
time PCR for miRNAs and mRNAs detection were 
performed as previously described [22]. For mRNAs 
detection the following QuantiTect primers (Qiagen) were 
used: CTNNB1 (QT00077882), MYC (QT00035406), 
PTEN (QT00035406), AKT1 (QT00085379), AKT2 
(QT00085001), AKT3 (QT00082138), OCT4 (POU5F1: 
QT00210840), SOX2 (QT00237601), NANOG 
(QT01025850), CXCR4 (QT00223188), VEGFA 
(QT01010184), H4 (HIST4H4: QT00218050) and MKI67 
(QT00014203). The relative amount of mRNAs and 
miRNAs was normalized to GAPDH (QT01192646) and 
U6 snRNA (203907, Exiqon A/S), respectively. Data were 
calculated using the comparative 2-ΔΔCt method [55].
Western blot
Cell lysates and protein samples were prepared 
as previously reported [60]. Proteins were resolved by 
SDS-polyacrylamide gel electrophoresis and transferred 
to a nitrocellulose membrane (Bio-Rad) for detection 
with primary antibodies against SPIN1 (diluted 1:500, 
19531-1-AP; Proteintech Group, Inc., Rosemont, IL, 
USA), CTNNB1 (diluted 1:500, sc-59737, Santa Cruz 
Biotechnology), MYC (diluted 1:500, sc-40, Santa Cruz 
Biotechnology), PTEN (diluted 1:500, sc-9145, Santa Cruz 
Biotechnology), AKT1/2/3 (diluted 1:500, sc-8312, Santa 
Cruz Biotechnology), p-AKT1/2/3 (Ser 473)-R (diluted 
1:500, sc-7985-R, Santa Cruz Biotechnology), OCT 3/4 
(diluted 1:300, sc-5279, Santa Cruz Biotechnology), SOX2 
(diluted 1:300, sc-20088, Santa Cruz Biotechnology), 
NANOG (diluted 1:300, sc-293121, Santa Cruz 
Biotechnology) and ACTIN (diluted 1:500, A5060, Sigma-
Aldrich). The membranes were then incubated with the 
appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibodies (diluted 1:5000, Perce, Thermo 
Fisher Scientific). The protein bands were revealed with an 
enhanced chemiluminescence detection system (ECL; Bio-
Rad) and visualized by ChemiDoc XRS system (Bio-Rad) 
and Quality One 4.5.2 (Biorad) software. Finally, protein 
levels were normalized using ACTIN levels. Protein bands 
were quantified densitometrically.
Statistical analysis
Data were represented as mean ± S.D. The 
significance of the differences between groups was 
assessed with a two-tailed Student’s t-test using Microsoft 
Excel. Differences were considered significant when 
P<0.05.
The relationship between miR-29b-1-5p and 
SPIN1 expression was determined by evaluating 
Pearson’s correlation coefficient (r). This coefficient, for 
continuous (interval level) data, ranges from -1 to +1. A 
correlation>0.8 is generally described as strong, whereas 
a correlation <0.5 is described as weak.
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